Phillip Mullin Becomes Louisiana's First Pediatric Recipient of Lyfgenia

Phillip Mullin, 15, is the first child in Louisiana to receive Lyfgenia, a stem cell gene therapy that has functionally cured his sickle cell disease. The treatment marks a shift in how the state handles pediatric blood disorders, ending a period in which Mullin spent more than 100 visits in hospitals.

Sickle cell disease causes abnormal red blood cells, leading to pain, infection, and stroke, according to the Centers for Disease Control and Prevention. For Mullin, the condition defined his adolescence through repeated admissions and sleepless nights. His mother, Shataka Figgins, described the discharge as a moment to unpack the fear of losing him, saying she will now focus on the young man who survived the illness.

The path to his cure began with a specific medical intervention at Manning Family Children's Hospital in New Orleans. The hospital, named in part after Archie Manning, hosted a ceremony on Friday morning to mark the completion of Mullin's treatment. Archie Manning attended the event and called the outcome a miracle, praising Mullin for his remarkable mind and resilience.

Mullin addressed the audience on Friday, stating that sacrifices are necessary to gain new strengths. He acknowledged the pain of the process but said enduring it leaves one with a heart strong enough to overcome obstacles. He also credited his sister, Paige, with being his constant support, noting that she is always there regardless of the distance between them. Paige described the moment as emotional, expressing surprise and joy that her brother had this opportunity.

Mullin plans to return to school with the goal of becoming a hematologist/oncologist. He wants to practice medicine that relates to patients with sickle cell disease, drawing on his own experience to understand their journey. For the immediate future, he plans to sleep in his own bed in Alexandria and build Legos with his baby sister.

The discharge concludes a long medical history for the Alexandria teen. His case stands as the state's first instance of a pediatric patient receiving this specific gene therapy, a treatment option that previously required travel or waiting for availability in other regions.